



Prolia Network Referral Program Participants

To: CSPN Members
From: CSPN Corporate
Date: September 20, 2011
Re: CSPN enters into Referral Network Program with Amgen

PHASE I

Congratulations on being chosen as an integral member of the Prolia hub which will mean a significant amount of referrals for this product will pass to our membership.

PHASE II

Thank you for participating in our webinars/conference calls on September 7th and 8th. We are happy to announce the Phase Two has begun in this program. Following the webinar/conference calls, Rick Hertz from Amgen sent an email to the Prolia Representatives covering your pharmacy to move ahead with the 2nd part of the program. This means that the reps will soon be visiting your pharmacy within the next couple of weeks to meet with you to introduce themselves and understand your pharmacy's services and explain more about the Prolia program and the activity with the program. Please show all courtesy to these representatives as they will be responsible for sending the Prolia referrals your way.

The terms of the agreement state that CSPN Member Pharmacies will become a part of the Prolia Hub which will allow CSPN Pharmacies to become part of the Prolia Pharmacy Finder Program, an informational database of pharmacies. Through this informational resource, healthcare professionals will receive a list of pharmacies, based on geographical parameters identified by the healthcare professional, that either stock Prolia® or can obtain Prolia® within 48 hours. The list will also contain contact information for each pharmacy listed and a description of other relevant services available at the pharmacy, such as prior authorization assistance and injections services.

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia be administered by a health professional every six months as a single subcutaneous injection. For more information about Prolia, please visit www.proliaplus.com.

CSPN in partnership with Amgen have been successful in getting recognition for our community based model and the value it can provide through our high touch model of patient care.

The success of this program is directly attributable to the dedication of the CSPN Member Pharmacies that participate. Remember our success is dependent on the collective efforts of all our members. Thank you again for your cooperation and we look forward to the opportunity of sending these patients and discounts to you.

Should you have any questions or concerns regarding the program, feel free to reach out us at the Corporate Office, 1.866.907.CSPN or speyton@cspnr.com

401 Pilgrim Lane, Suite 201, Drexel Hill, PA 19026
(p) 1.866.907.2776 / (f) 610.449.3405